ZA200004482B - Process for the synthesis of HIV protease inhibitors. - Google Patents
Process for the synthesis of HIV protease inhibitors. Download PDFInfo
- Publication number
- ZA200004482B ZA200004482B ZA200004482A ZA200004482A ZA200004482B ZA 200004482 B ZA200004482 B ZA 200004482B ZA 200004482 A ZA200004482 A ZA 200004482A ZA 200004482 A ZA200004482 A ZA 200004482A ZA 200004482 B ZA200004482 B ZA 200004482B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- resultant
- reacting
- approximately
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 13
- 230000015572 biosynthetic process Effects 0.000 title description 7
- 238000003786 synthesis reaction Methods 0.000 title description 7
- 239000004030 hiv protease inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 63
- -1 tetrahydrofuryloxy carbonyl group Chemical group 0.000 claims description 19
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 claims description 6
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 4
- 125000006242 amine protecting group Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- 229940075894 denatured ethanol Drugs 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- AUYHZFAGBOOPMD-CMXBXVFLSA-N n-[(2r,3s)-3-amino-2-hydroxy-4-phenylbutyl]-n-(2-methylpropyl)-4-nitrobenzenesulfonamide;hydrochloride Chemical compound Cl.C([C@H](N)[C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 AUYHZFAGBOOPMD-CMXBXVFLSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 2
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical group OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- GDHPHPNSFSAFPD-ZETCQYMHSA-N [(3s)-oxolan-3-yl] imidazole-1-carboxylate Chemical compound C1=CN=CN1C(=O)O[C@H]1CCOC1 GDHPHPNSFSAFPD-ZETCQYMHSA-N 0.000 description 1
- ZMNCIAGFQBUWTJ-OEMFJLHTSA-N [(3s)-oxolan-3-yl] n-[(2s,3r)-3-hydroxy-4-[2-methylpropyl-(4-nitrophenyl)sulfonylamino]-1-phenylbutan-2-yl]carbamate Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(=CC=1)[N+]([O-])=O)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 ZMNCIAGFQBUWTJ-OEMFJLHTSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003226 decolorizating effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- CQGKCZKCWMWXQP-XZOQPEGZSA-N tert-butyl n-[(2s,3r)-3-hydroxy-4-[2-methylpropyl-(4-nitrophenyl)sulfonylamino]-1-phenylbutan-2-yl]carbamate Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(=CC=1)[N+]([O-])=O)NC(=O)OC(C)(C)C)C1=CC=CC=C1 CQGKCZKCWMWXQP-XZOQPEGZSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9805898.5A GB9805898D0 (en) | 1998-03-20 | 1998-03-20 | Process for the sythesis of hiv protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200004482B true ZA200004482B (en) | 2001-11-28 |
Family
ID=10828884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200004482A ZA200004482B (en) | 1998-03-20 | 2000-08-29 | Process for the synthesis of HIV protease inhibitors. |
Country Status (32)
Country | Link |
---|---|
US (1) | US6281367B1 (is) |
EP (1) | EP1066276B1 (is) |
JP (1) | JP3363439B2 (is) |
KR (1) | KR100555278B1 (is) |
CN (1) | CN1308319C (is) |
AP (1) | AP1226A (is) |
AT (1) | ATE242772T1 (is) |
AU (1) | AU751534B2 (is) |
BR (1) | BR9908970A (is) |
CA (1) | CA2324217C (is) |
CZ (1) | CZ299193B6 (is) |
DE (1) | DE69908761T2 (is) |
DK (1) | DK1066276T3 (is) |
EA (1) | EA003022B1 (is) |
EE (1) | EE04750B1 (is) |
ES (1) | ES2203090T3 (is) |
GB (1) | GB9805898D0 (is) |
HK (1) | HK1032047A1 (is) |
HR (1) | HRP20000609B1 (is) |
HU (1) | HUP0105439A3 (is) |
ID (1) | ID26587A (is) |
IL (1) | IL138127A (is) |
IS (1) | IS2273B (is) |
NO (1) | NO317648B1 (is) |
NZ (1) | NZ506563A (is) |
PL (1) | PL201810B1 (is) |
PT (1) | PT1066276E (is) |
RS (1) | RS49954B (is) |
SK (1) | SK283939B6 (is) |
TR (1) | TR200002698T2 (is) |
WO (1) | WO1999048885A1 (is) |
ZA (1) | ZA200004482B (is) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3657002B2 (ja) | 1992-08-25 | 2005-06-08 | ジー.ディー.サール アンド カンパニー | レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド |
US6548706B2 (en) * | 1999-12-23 | 2003-04-15 | Aerojet Fine Chemicals Llc | Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines |
EP2314564A3 (en) * | 1999-12-23 | 2012-04-04 | Ampac Fine Chemicals LLC | Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines |
EA007120B8 (ru) * | 2002-05-16 | 2012-03-30 | Тиботек Фармасьютикалз Лтд. | Псевдополиморфные формы ингибитора вич-протеазы |
JP4818124B2 (ja) * | 2003-12-23 | 2011-11-16 | テイボテク・フアーマシユーチカルズ・リミテツド | (3R,3aS,6aR)−ヘキサヒドロフロ〔2,3−b〕フラン−3−イル(1S,1R)−3−〔〔(4−アミノフェニル)スルホニル〕(イソブチル)アミノ〕−1−ベンジル−2−ヒドロキシプロピルカルバマートの製造方法 |
TWI482775B (zh) | 2008-09-01 | 2015-05-01 | Tibotec Pharm Ltd | 用於製備(3r,3as,6ar)-六氫呋喃并〔2,3-b〕呋喃-3-基(1s,2r)-3-〔〔(4-胺基苯基)磺醯基〕(異丁基)胺基〕-1-苯甲基-2-羥基丙基胺基甲酸酯之方法 |
ES2688925T3 (es) | 2010-01-27 | 2018-11-07 | Viiv Healthcare Company | Tratamiento antiviral |
WO2012032389A2 (en) | 2010-09-10 | 2012-03-15 | Lupin Limited | Process for preparation of substantially pure fosamprenavir calcium and its intermediates |
CN111233794A (zh) * | 2020-03-27 | 2020-06-05 | 江巨东 | 一种安普那韦的精制方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1071930A (zh) * | 1991-07-10 | 1993-05-12 | 伊莱利利公司 | 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂 |
JP3657002B2 (ja) * | 1992-08-25 | 2005-06-08 | ジー.ディー.サール アンド カンパニー | レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド |
IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
-
1998
- 1998-03-20 GB GBGB9805898.5A patent/GB9805898D0/en not_active Ceased
-
1999
- 1999-03-18 CZ CZ20003457A patent/CZ299193B6/cs not_active IP Right Cessation
- 1999-03-18 PL PL342602A patent/PL201810B1/pl not_active IP Right Cessation
- 1999-03-18 US US09/646,277 patent/US6281367B1/en not_active Expired - Lifetime
- 1999-03-18 NZ NZ506563A patent/NZ506563A/en unknown
- 1999-03-18 JP JP2000537868A patent/JP3363439B2/ja not_active Expired - Lifetime
- 1999-03-18 WO PCT/GB1999/000852 patent/WO1999048885A1/en active IP Right Grant
- 1999-03-18 BR BR9908970-0A patent/BR9908970A/pt not_active Application Discontinuation
- 1999-03-18 CN CNB998042242A patent/CN1308319C/zh not_active Expired - Fee Related
- 1999-03-18 EE EEP200000568A patent/EE04750B1/xx not_active IP Right Cessation
- 1999-03-18 AU AU29475/99A patent/AU751534B2/en not_active Ceased
- 1999-03-18 KR KR1020007010359A patent/KR100555278B1/ko not_active IP Right Cessation
- 1999-03-18 CA CA002324217A patent/CA2324217C/en not_active Expired - Fee Related
- 1999-03-18 RS YUP-559/00A patent/RS49954B/sr unknown
- 1999-03-18 PT PT99910543T patent/PT1066276E/pt unknown
- 1999-03-18 TR TR2000/02698T patent/TR200002698T2/xx unknown
- 1999-03-18 EA EA200000859A patent/EA003022B1/ru unknown
- 1999-03-18 ID IDW20001857A patent/ID26587A/id unknown
- 1999-03-18 AT AT99910543T patent/ATE242772T1/de not_active IP Right Cessation
- 1999-03-18 DK DK99910543T patent/DK1066276T3/da active
- 1999-03-18 EP EP99910543A patent/EP1066276B1/en not_active Expired - Lifetime
- 1999-03-18 SK SK1373-2000A patent/SK283939B6/sk not_active IP Right Cessation
- 1999-03-18 DE DE69908761T patent/DE69908761T2/de not_active Expired - Lifetime
- 1999-03-18 AP APAP/P/2000/001911A patent/AP1226A/en active
- 1999-03-18 HU HU0105439A patent/HUP0105439A3/hu unknown
- 1999-03-18 IL IL13812799A patent/IL138127A/xx not_active IP Right Cessation
- 1999-03-18 ES ES99910543T patent/ES2203090T3/es not_active Expired - Lifetime
-
2000
- 2000-08-29 ZA ZA200004482A patent/ZA200004482B/en unknown
- 2000-08-29 IS IS5605A patent/IS2273B/is unknown
- 2000-09-15 HR HR20000609A patent/HRP20000609B1/xx not_active IP Right Cessation
- 2000-09-19 NO NO20004664A patent/NO317648B1/no not_active IP Right Cessation
-
2001
- 2001-03-30 HK HK01102333A patent/HK1032047A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05230011A (ja) | 2,3:4,5−ビス−O−(1−メチルエチリデン)−β−D−フルクトピラノースおよび(1−メチルシクロヘキシル)メタノールのクロロサルフエートおよびスルフアメート誘導体の製法 | |
EP1066276B1 (en) | Process for the synthesis of hiv protease inhibitors | |
EP3199536B1 (en) | Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof | |
CN104557583B (zh) | 一种合成γ-氨基丁酸类手性化合物的方法 | |
EP1904469A1 (en) | New pyrocatechin derivatives | |
EP1071654A1 (en) | A process for preparing chiral (s)-2,3-disubstituted-1-propylamine derivatives | |
MXPA00008925A (en) | Process for the synthesis of hiv protease inhibitors | |
RU2761167C1 (ru) | Способ получения картолина-2 | |
US4603211A (en) | Process for the preparation of 1,2-benzoxathiine derivatives | |
RU2746753C1 (ru) | Способ получения N-(изопропоксикарбонил)этилендиамина | |
EP1188744B1 (en) | Process for producing optically active 1H-3-aminopyrrolidine and derivatives thereof | |
CN114901647A (zh) | 具有改进的选择性的制备芳基2-四唑-2-基酮的方法 | |
CN116396265A (zh) | 一种替卡格雷中间体的制备方法 | |
CN115368261A (zh) | N-烯丙基-n-苄基-2-(苄基氨基)乙酰胺的合成方法 | |
CN116354869A (zh) | 一种环己烯类抗病毒化合物的合成工艺 | |
CN112028827A (zh) | 一种奈他地尔关键中间体的制备方法 | |
WO2011116933A1 (en) | Process for the preparation of 2-substituted 4-amino-5-cyanopyrimidines | |
WO2004063175A1 (en) | A novel and an improved process for the preparation of (s)-4-(4-aminobenzyl)-2- oxazolidinone | |
KR20050062976A (ko) | 2,3:4,5-비스-오-(1-메틸에틸리덴)-베타-디-프럭토피라노즈설파메이트의 새로운 개량된 제조방법 | |
HU200999B (en) | Process for producing n-methyl-(2,3-dihydro-2,2-dimethyl-7-benzofuranyl)-carbamate |